NOVEL REGULATORS OF THE IFN/GAMMA MHC CLASS II PATHWAY

IFN-γ和MHCII类表达的上调已经被证实， 在肿瘤模型中进行了研究，并发现其对控制 一系列癌症的症状。IFN-γ治疗， MHC II类的主要诱导物，可以通过以下方式促进肿瘤排斥反应： 激活免疫反应这项建议的目的是 鉴定诱导MHC II类所必需的基因 IFN-γ的基因表达。这将通过使用 基因互补以确定G2 A和G3 A中的缺陷 突变细胞系，这两个都是-选择性缺陷的干扰素- γ诱导II类相关基因，但不是在IFN-γ 经典途径的γ诱导。诸如互补 方法，反义文库将用于鉴定另外的 IFN-γ诱导MHC II类分子所需的基因 γ的这项工作应该通过以下方式促进癌症的治疗： 肿瘤增强的潜在靶点的鉴定 免疫治疗的排斥反应。

Upregulation of IFN-gamma and MHC class II expression has been studied in tumor models and is found to be effective for the control of a number of types of cancer. Treatment with IFN-gamma, the main inducer of MHC class II,can promote tumor rejection by activating immune responses. The purpose of this proposal is to identify genes which are essential for the induction of MHC class II gene expression by IFN-gamma. This will be accomplished by using gene complementation to determine the defect in G2A and G3A mutant cell lines, both of which are - selectively defective in IFN- gamma induction of class II-associated genes, but not in the IFN- gamma induction of the classical pathway. As a complementary approach, an antisense library will be used to identify additional genes selectively required for MHC class II induction by IFN- gamma. This work should promote the treatment of cancer through the identification of potential targets for the enhancement of tumor rejection by immunotherapy.